ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Roche Receives FDA approval for VENTANA ALK CDx Assay with LORBRENA americanpharmaceuticalreview
March 12, 2021Roche announced US Food and Drug Administration (FDA) approval of the VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible for treatment with Pfizer's drug LORBRENA? ... -
FDA Approves Lorlatinib for Metastatic ALK-Positive NSCLC americanpharmaceuticalreview
March 09, 2021The U.S. Food and Drug Administration (FDA) has granted regular approval to lorlatinib (Lorbrena, Pfizer) for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive ...
Pharma Sources Insight January 2025
